Arca Biopharma | ABIO - Sales Revenues


Arca Biopharma reported 0 in Sales Revenues for its fiscal quarter ending in March of 2025.





Sales Change Date
Alterity Therapeutics Limited AUD 596.04K 584.66K Dec/2025
Amgen USD 8.62B 1.28B Mar/2026
Arca Biopharma 0 0 Mar/2025
Biogen USD 2.25B 30M Mar/2026
Brainstorm Cell Therapeutics 0 0 Mar/2025
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Capricor Therapeutics USD 11.13M 8.87M Dec/2024
Cipla INR 65.41B 9.77B Mar/2026
Clal Biotechnology ILS 3.41M 2M Dec/2022
Compugen USD 6.35M 60.98M Mar/2026
CSL USD 8.33B 4.79B Dec/2025
Cytokinetics USD 19.35M 1.59M Mar/2026
Daiichi Sankyo JPY 587B 28.89B Mar/2026
Gilead Sciences USD 7B 930M Mar/2026
GlaxoSmithKline GBP 7.63B 991M Mar/2026
Grifols EUR 2B 306.7M Mar/2026
Laboratory Of America USD 3.54B 20M Mar/2026
Myriad Genetics USD 200.4M 9.4M Mar/2026
Otsuka Holdings JPY 630.34B 19.81B Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
United Therapeutics USD 781.5M 8.7M Mar/2026